This website uses cookies
Read our Privacy policy and Terms of use for more information.
GLP1
+2

May 19, 2026
•
13 min read
Istanbul gave us the answers we have been waiting for. Obesity is now being treated like every other chronic disease — and the data is on the right side of history.

Obesity
+1

May 16, 2026
•
7 min read
If I could ask every patient, every reader, every person I know to change just one thing about their daily life — this would be it.

GLP1
+2

Apr 22, 2026
•
17 min read
The science of sequencing GLP-1 therapy and bariatric surgery — and why the answer is more complicated than anyone wants to admit.

GLP1
+3

Mar 27, 2026
•
15 min read
It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.

GLP1
+2

Mar 21, 2026
•
13 min read
A new BMJ Medicine analysis quantifies what happens to cardiovascular risk after GLP-1 discontinuation. The numbers are striking. The framing some are applying to them is wrong.

GLP1
+3

Mar 19, 2026
•
14 min read
Retatrutide may be the first pharmacotherapy to approach bariatric surgery–level weight loss. Phase 3 data now confirm what phase 2 only suggested: this is a categorically different molecule.

GLP1
+1

Mar 6, 2026
•
20 min read
Across randomized trials, stopping GLP-1/dual incretin therapy is typically followed by clinically meaningful weight regain and loss of cardiometabolic gains—often within months—highlighting obesity as a chronic, relapsing condition.

GLP1
+1

Feb 28, 2026
•
12 min read
The neuroscience and evolutionary biology behind a widely misunderstood disease

Obesity
+1

Feb 25, 2026
•
12 min read
How history can inform a more equitable future.

SUBSCRIBE TO MY NEWSLETTER